• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

司来吉兰的抗帕金森病疗效源于可能是对症的短暂改善。

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.

作者信息

Schulzer M, Mak E, Calne D B

机构信息

Department of Medicine, University Hospital, Vancouver, BC, Canada.

出版信息

Ann Neurol. 1992 Dec;32(6):795-8. doi: 10.1002/ana.410320614.

DOI:10.1002/ana.410320614
PMID:1471871
Abstract

We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.

摘要

我们对帕金森研究小组在对司来吉兰进行调查后发表的结果所推导的风险函数进行了分析。我们的研究结果表明,司来吉兰的作用是短暂的而非持续的。我们还推断,这种效应可能是通过症状缓解而非神经保护来介导的。

相似文献

1
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.司来吉兰的抗帕金森病疗效源于可能是对症的短暂改善。
Ann Neurol. 1992 Dec;32(6):795-8. doi: 10.1002/ana.410320614.
2
Antiparkinson efficacy of deprenyl. DATATOP Steering Committee of Parkinson Study Group.司来吉兰的抗帕金森病疗效。帕金森研究组DATATOP指导委员会。
Ann Neurol. 1993 Oct;34(4):634. doi: 10.1002/ana.410340423.
3
The effect of deprenyl and levodopa on the progression of Parkinson's disease.司来吉兰和左旋多巴对帕金森病进展的影响。
Ann Neurol. 1995 Nov;38(5):771-7. doi: 10.1002/ana.410380512.
4
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.帕金森病神经保护的临床试验:长期司来吉兰和α-生育酚治疗。
J Neural Transm Suppl. 1994;43:171-81.
5
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.持续使用司来吉兰(丙炔苯丙胺)对左旋多巴治疗的帕金森病的影响:帕金森病去甲丙咪嗪和生育酚抗氧化治疗试验的随机安慰剂对照扩展研究
Ann Neurol. 2002 May;51(5):604-12. doi: 10.1002/ana.10191.
6
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.DATATOP:十年神经保护研究。帕金森研究小组。司来吉兰与维生素E对帕金森病的抗氧化治疗。
Ann Neurol. 1998 Sep;44(3 Suppl 1):S160-6.
7
Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.R-(-)-司来吉兰治疗帕金森病伴发“开-关”现象的双盲试验。
J Neural Transm Suppl. 1987;25:123-9.
8
Treatment of Parkinson's disease.帕金森病的治疗
Curr Opin Neurol Neurosurg. 1993 Jun;6(3):339-43.
9
Deprenyl in Parkinson's disease.
Ann Neurol. 1996 Aug;40(2):268-9. doi: 10.1002/ana.410400229.
10
Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects.
Can J Neurol Sci. 1992 Feb;19(1 Suppl):142-6.

引用本文的文献

1
Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs.调节活性氧稳态作为常用药物的多效性作用
Front Aging. 2022 Jun 14;3:905261. doi: 10.3389/fragi.2022.905261. eCollection 2022.
2
Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.抗帕金森病药物:临床显著的药物相互作用和不良反应及其管理。
CNS Drugs. 1998 Apr;9(4):291-310. doi: 10.2165/00023210-199809040-00005.
3
Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.
司来吉兰逆转雄性小鼠β₂₅₋₃₅诱导的认知缺陷。
Neurochem Res. 2013 Nov;38(11):2287-94. doi: 10.1007/s11064-013-1137-6. Epub 2013 Sep 5.
4
Disease progression, drug action and Parkinson's disease: why time cannot be ignored.疾病进展、药物作用与帕金森病:为何时间不容忽视。
Eur J Clin Pharmacol. 2008 Feb;64(2):207-16. doi: 10.1007/s00228-007-0427-9. Epub 2007 Dec 19.
5
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.帕金森病的疾病进展与药效学——左旋多巴及其他治疗的功能保护证据
J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311. doi: 10.1007/s10928-006-9012-6. Epub 2006 Apr 20.
6
Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin.针对趋化因子、谷氨酸和促红细胞生成素受体的HIV-1相关痴呆的实验性及潜在未来治疗方法
Neurotox Res. 2005 Oct;8(1-2):167-86. doi: 10.1007/BF03033828.
7
Early detection of Parkinson's disease. Implications for treatment.
Drugs Aging. 1996 Sep;9(3):159-68. doi: 10.2165/00002512-199609030-00002.
8
Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity.司来吉兰对MPP⁺诱导的多巴胺能毒性的神经元保护和挽救作用。
J Neural Transm Gen Sect. 1995;100(1):53-61. doi: 10.1007/BF01276865.
9
Drug management of Parkinson's disease.帕金森病的药物治疗
Can Fam Physician. 1996 May;42:946-52.
10
Selegiline in Parkinson's disease.司来吉兰治疗帕金森病
BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583.